9 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 1, 8 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Terminated 2, Recruiting 1 |
| Phase 2 | 8 | Completed 6, Active not recruiting 1, Terminated 1 |
| Not applicable | 1 | Withdrawn 1 |
Follow 1-methyltryptophan: new trials by email Literature Review of 1-methyltryptophan trials Research Report on 1-methyltryptophan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer Indoximod, Ibrutinib, Cyclophosphamide - Ependymoma, Medulloblastoma | Phase 1 | Recruiting | Theodore S. Johnson | 37 | 2022-02-08 | 2026-01-09 |
| Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Indoximod, Partial Radiation, Full-dose Radiation - Glioblastoma, Medulloblastoma | Phase 2 | Active not recruiting | Theodore S. Johnson | 130 | 2019-10-02 | 2026-01-08 |
| A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma Pembrolizumab, Nivolumab, Indoximod - Melanoma | Phase 2 | Terminated | NewLink Genetics Corporation | 21 | 2017-12-08 | 2022-09-27 |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer Docetaxel, Tergenpumatucel-L, Indoximod - Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer | Phase 1 | Terminated | NewLink Genetics Corporation | 16 | 2016-01-01 | 2022-04-06 |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors Indoximod, Temozolomide, Conformal Radiation - Glioblastoma Multiforme, Glioma | Phase 1 | Completed | NewLink Genetics Corporation | 81 | 2015-10-01 | 2020-06-04 |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Nab-Paclitaxel, Gemcitabine, Indoximod - Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 157 | 2014-08-01 | 2026-04-03 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 131 | 2014-07-01 | 2026-05-29 |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Indoximod, Temozolomide, Bevacizumab - Glioblastoma Multiforme, Glioma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 160 | 2014-03-01 | 2024-03-27 |
| Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Docetaxel, Placebo, Indoximod - Metastatic Breast Cancer | Phase 2 | Completed | NewLink Genetics Corporation | 169 | 2013-02-01 | 2020-05-28 |
| C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer Adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-D-tryptophan, Carbon C 11 alpha-methyltryptophan - Breast Cancer | Not applicable | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2013-01-01 | 2017-02-23 | |
| Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Indoximod, Sipuleucel-T, Placebo - Metastatic Prostate Cancer | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 47 | 2012-10-01 | 2020-04-03 |
| 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors 1-methyl-d-tryptophan, docetaxel, diagnostic laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-09-01 | 2014-07-24 |
| Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer adenovirus-p53 transduced dendritic cell (DC) vaccine, 1-methyl-d-tryptophan, Laboratory biomarker analysis - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 44 | 2009-12-28 | 2018-04-11 |
| IDO Inhibitor Study for Relapsed or Refractory Solid Tumors 1-methyl-D-tryptophan - Breast Cancer, Lung Cancer | Phase 1 | Terminated | NewLink Genetics Corporation | 17 | 2008-08-01 | 2020-05-28 |
| 1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery 1-methyl-d-tryptophan, pharmacological study, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 52 | 2007-10-01 | 2014-07-24 |
Brain Neoplasms (4) · Breast Neoplasms (4) · Glioblastoma (4) · Ependymoma (3) · Medulloblastoma (3) · Melanoma (3) · Diffuse Intrinsic Pontine Glioma (2) · Glioma (2) · Gliosarcoma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
NewLink Genetics Corporation (8) · H. Lee Moffitt Cancer Center and Research Institute (2) · National Cancer Institute (NCI) (2) · Theodore S. Johnson (2) · Masonic Cancer Center, University of Minnesota (1)
United States (14) · Poland (1)
Gene Kennedy, MD (2) · Hatem Soliman (2) · Charles J. Link, M.D. (1) · Hatem Soliman, M.D. (1) · Scott Antonia (1) · Shilpa Gupta, M.D. (1) · Theodore S Johnson, MD, PhD (1) · Theodore S. Johnson, MD, PhD (1)
PMID 20930628, PMID 33151286, PMID 37534996, PMID 37715730
P30CA076292 (3), N01CM00100 (2), R01CA229646 (1)